Skip to main content

Table 6 Nerve excitability parameters. Secondary endpoints

From: High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study

 

W0

W24

W48

Absolute change between W0 and W48

p-value

Strength-duration time constant (ms)

0.13 (0.12;0.36)

0.27 (0.12;0.40)

0.32 (0.14;0.36)

0.05 (-0.01;0.14)

.039

Rheobase (mA)

12.50 (7.02;20.61)

10.28 (7.22;18.39)

7.31 (3.72;11.39)

-4.21 (-9.22;-0.78)

 < .001

Supernormality (%)

116.0 (101.4;134.9)

128.8 (109.3;139.1)

128.8 (108.1;139.0)

7.0 (-4.3;25.9)

.213

Refractoriness (%)

33.70 (16.50;53.50)

27.10 (0.00;42.80)

28.90 (11.60;42.80)

-15.90 (-24.40;11.60)

.330

Minimum absolute refractory period (ms)

1.30 (1.10;1.62)

1.34 (1.14;1.56)

1.34 (1.14;1.56)

0.00 (-0.10;0.04)

.923

Maximum absolute refractory period (ms)

2.12 (1.70;2.58)

2.02 (1.90;3.20)

2.12 (1.70;2.40)

-0.02 (-0.50;0.40)

.313

  1. Missing data at W48 were imputed with the LOCF method (W24 for patient #04, CIDP group). The P-value was calculated with the Wilcoxon signed rank test. The results are expressed as median (IQR) calculated in all patients (n = 15)